Immunohistochemistry analysis of serial tumor biopsies from patients with HER2-negative breast cancer who received lower dose sunitinib or bevacizumab before standard chemotherapy showed modulation of vessel morphology in tumor tissue along with suppression of tumor cell proliferation. Here, ERBB2 is linked to breast carcinoma.